Insulin pump therapy ... which has been supported by Novo Nordisk, Medtronic, Roche Diagnostics, Boehringer Ingelheim, and Lilly through institutional research grants. R.W.H. has not received ...

and insulin pumps, which also make therapy more convenient, are already gaining in popularity. Novo Nordisk is investing heavily in another oral formulation: its next-generation GLP-1 analogue ...

For Novo Nordisk, a company still rooted in principles ... This formulation will be especially important for type 1 patients who use insulin pumps, a trend likely to develop in coming decades.

Dr Vandana Dhume, on Monday stated that over 26.4 per cent of Goa’s population is living with diabetes, marking a serious public health concern for the State. Speaking at a programme, she explained ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk ... Back in Denmark, within months, they set up the Nordisk Insulin Company. In keeping with their agreement ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations, said that its net profit in the third quarter hit 27.3 billion Danish kroner, just above an LSEG ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs ...